SEATTLE, WA--(MARKET WIRE)--Jun 4, 2007 -- Targeted Genetics Corporation (NasdaqCM:TGEN - News) today announced additional data from the dose escalation arm of the ongoing Phase I/II clinical study of tgAAC94 in patients with inflammatory arthritis. Philip J. Mease, M.D., clinical professor at the University of Washington School of Medicine, chief of rheumatology clinical research at the Swedish Medical Center, practicing physician with Seattle Rheumatology Associates and the lead investigator on the trial, presented the data in an oral presentation yesterday at the 10th Annual Meeting of the American Society of Gene Therapy in Seattle (ASGT).
